Strategic partnerships Ratio Therapeutics is actively expanding manufacturing collaborations, including a multi-faceted alliance with PharmaLogic Holdings Corp to support clinical development and commercialization readiness of lead radiopharmaceutical RTX-2358, indicating strong upside for CDMO and supply chain partners.

Expansion footprint The company has invested in new and expanded facilities in Utah, including a planned 65,000-square-foot radiopharmaceutical research and manufacturing site, signaling capacity growth and opportunities for equipment suppliers, contract manufacturers, and logistics providers.

Leadership addition Recent hire of a Chief Medical Officer and strategic leadership timing suggests a push toward clinical execution, medical affairs, and translational partnerships—opening dialogues for Clinical Research Organizations, medical communications firms, and advisory service collaborations.

Theranostic portfolio Ratio’s Trillium targeting scaffold enables both diagnostic imaging and therapeutic radiopharmaceuticals, creating cross-sell opportunities with imaging consultants, radiopharma distributors, and radiology-focused service providers seeking integrated theranostic solutions.

Funding and scale With reported revenue in the tens of millions and a $50M funding level, Ratio presents a credible growth client for equipment vendors, radiochemical supply chain partners, and contract research and manufacturing service providers aiming to support GMP manufacturing and early-phase trials.